Biopartners Announces CHMP Positive Opinion for its biosimilar Recombinant Human Growth Hormone – Valtropin™

Baar, Switzerland 24th February 2006: BioPartners, a global, privately owned biopharmaceuticals company has received a positive opinion from the European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP) for its similar biological medicinal product Valtropin™, containing recombinant human growth hormone.
Commenting on this, Professor Paul Saenger, Professor of Paediatrics at the Albert Einstein College of Medicine in New York, USA and Immediate Past President, Lawson Wilkins Paediatric Endocrine Society said “if it is granted marketing authorisation, Valtropin™ will provide paediatric endocrinologists with a more cost-effective treatment option for growth disorders compared to the currently marketed growth hormone preparations and this in turn allow us to treat more patients, which is great news”.

“A positive opinion from the CHMP is a key milestone in our efforts and it demonstrates BioPartners’ commitment and dedication to the development of competitive biosimilar products” stated Mr Jean-Noël Treilles, CEO of BioPartners. “We anticipate an approval for Valtropin™ and this will strengthen our development programme for our innovative delayed release rhGH formulation currently in Phase III. We are looking forward to providing healthcare professionals and patients with this innovative treatment in the very near future”.